Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Phase 3 Completed 70 enrolled French National Agency for Research on AIDS and Viral Hepatitis

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity. This study will test the efficacy and safety of a once daily antiretroviral regimen in HIV-tuberculosis coinfected patients.

Timeline

Start: 2006-01
Primary completion: 2009-11
Completion: 2009-11

Publications

Results Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chene G; ANRS 129 BKVIR Trial Group. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efavirenz	Other / unclassified	800 mg	—
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	—
Subject	emtricitabine	Other / unclassified	200 mg	—

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Summary

Timeline

Publications

Drugs

Indications